Thoratec (THOR) Commences CE Mark Clinical Trial for HeartMate III
Tweet Send to a Friend
Thoratec (Nasdaq: THOR) said today that its CE Mark Clinical Trial for HeartMate III commenced with the first patient implanted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE